This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
mg kg | 892 |
control group | 751 |
intensive care | 710 |
significantly higher | 646 |
ng ml | 600 |
blood pressure | 569 |
septic shock | 537 |
gene expression | 506 |
mean age | 480 |
present study | 474 |
two groups | 471 |
oxidative stress | 425 |
significant difference | 406 |
pg ml | 403 |
statistically significant | 402 |
amino acid | 402 |
cell lines | 391 |
risk factors | 388 |
mechanical ventilation | 380 |
care unit | 379 |
critically ill | 375 |
endothelial cells | 369 |
cell line | 361 |
insulin resistance | 359 |
significant differences | 358 |
amino acids | 348 |
type diabetes | 345 |
mg dl | 337 |
metabolic syndrome | 331 |
significantly increased | 331 |
nitric oxide | 328 |
blood flow | 323 |
results suggest | 318 |
blood samples | 303 |
mrna expression | 289 |
important role | 288 |
body weight | 281 |
ill patients | 276 |
significantly lower | 265 |
western blot | 258 |
diabetes mellitus | 258 |
peripheral blood | 251 |
smooth muscle | 248 |
years old | 245 |
inflammatory response | 242 |
significant increase | 241 |
chronic hepatitis | 240 |
organ failure | 239 |
hbv dna | 231 |
emergency department | 229 |
significantly reduced | 227 |
protein expression | 227 |
plasma levels | 225 |
logistic regression | 223 |
cell proliferation | 223 |
cardiac arrest | 223 |
serum levels | 221 |
cell death | 221 |
intravenous immunoglobulin | 219 |
specific ige | 218 |
breast cancer | 215 |
flow cytometry | 211 |
cancer cells | 209 |
growth factor | 209 |
apache ii | 205 |
risk factor | 201 |
heart failure | 200 |
critical care | 198 |
immune response | 197 |
adhesion molecules | 197 |
statistical analysis | 194 |
liver transplantation | 192 |
university hospital | 191 |
cardiac output | 191 |
liver disease | 190 |
side effects | 189 |
heart rate | 189 |
dependent manner | 186 |
results indicate | 185 |
increased risk | 181 |
renal failure | 181 |
icu patients | 180 |
data suggest | 180 |
performed using | 178 |
pregnant women | 174 |
mg ml | 174 |
septic patients | 173 |
one patient | 172 |
dna damage | 172 |
diabetic patients | 172 |
patients undergoing | 172 |
blood glucose | 171 |
respiratory failure | 170 |
ml kg | 169 |
significantly decreased | 169 |
patients admitted | 169 |
cd cd | 169 |
mrna levels | 168 |
ml min | 168 |
adipose tissue | 166 |
body mass | 165 |
myocardial infarction | 164 |
high levels | 162 |
epithelial cells | 162 |
wild type | 161 |
median age | 160 |
cardiac surgery | 158 |
health care | 157 |
necrosis factor | 157 |
molecular weight | 157 |
significantly different | 157 |
renal function | 157 |
cell cycle | 155 |
arterial pressure | 155 |
prospective study | 154 |
gestational age | 154 |
determine whether | 154 |
mass spectrometry | 153 |
group i | 152 |
immune system | 152 |
bone marrow | 152 |
time pcr | 149 |
positive correlation | 148 |
expression levels | 148 |
regression analysis | 147 |
arterial blood | 146 |
study period | 145 |
reactive oxygen | 145 |
cell surface | 145 |
patients treated | 145 |
healthy controls | 145 |
long term | 145 |
significant decrease | 144 |
patients without | 143 |
tumor necrosis | 143 |
lung injury | 142 |
allergic rhinitis | 142 |
severe sepsis | 142 |
coronary artery | 142 |
whole blood | 141 |
multiple organ | 141 |
medical center | 139 |
may contribute | 139 |
mass index | 138 |
measured using | 137 |
fatty acids | 136 |
acute respiratory | 136 |
nervous system | 135 |
kg day | 134 |
high risk | 133 |
endothelial cell | 133 |
hospital mortality | 133 |
previous studies | 133 |
mortality rate | 132 |
higher levels | 132 |
transcription factor | 132 |
results show | 132 |
significant reduction | 132 |
glucose tolerance | 131 |
cohort study | 131 |
pulmonary artery | 131 |
healthy volunteers | 130 |
patients received | 129 |
hepatocellular carcinoma | 129 |
inflammatory cytokines | 128 |
oxygen species | 128 |
analysis revealed | 128 |
protein levels | 128 |
significant correlation | 127 |
results showed | 126 |
findings suggest | 125 |
mechanically ventilated | 125 |
may play | 124 |
among patients | 123 |
three groups | 123 |
least one | 122 |
copies ml | 121 |
stem cells | 121 |
mean arterial | 121 |
cancer cell | 121 |
first time | 120 |
food allergy | 120 |
significantly associated | 120 |
respiratory distress | 120 |
cell viability | 119 |
blood loss | 119 |
acute phase | 119 |
tumor cells | 119 |
two patients | 118 |
uric acid | 118 |
skin prick | 117 |
study group | 117 |
cell types | 117 |
skeletal muscle | 116 |
blot analysis | 116 |
protein kinase | 115 |
muscle cells | 114 |
western blotting | 114 |
clinical trials | 114 |
observational study | 112 |
vascular resistance | 112 |
group ii | 112 |
neopterin levels | 112 |
binding protein | 112 |
real time | 111 |
within hours | 111 |
icu stay | 110 |
adult patients | 110 |
trauma patients | 110 |
left ventricular | 110 |
two different | 110 |
fat diet | 109 |
reactive protein | 109 |
central venous | 109 |
waist circumference | 108 |
pulmonary hypertension | 107 |
informed consent | 107 |
ii score | 107 |
organ dysfunction | 107 |
kg min | 107 |
lg ml | 107 |
molecular mechanisms | 106 |
predictive value | 106 |
analyzed using | 106 |
weight loss | 106 |
widely used | 105 |
retrospective study | 105 |
icu admission | 105 |
patients receiving | 104 |
ms ms | 104 |
healthy subjects | 103 |
cell adhesion | 103 |
increased levels | 102 |
extracellular matrix | 101 |
plasma membrane | 101 |
fatty acid | 101 |
signal transduction | 100 |
liver cirrhosis | 100 |
venous blood | 100 |
public health | 100 |
determined using | 100 |
glucose levels | 100 |
animal models | 100 |
transcription factors | 100 |
spinal cord | 99 |
may also | 99 |
consecutive patients | 99 |
commercially available | 99 |
oxygen saturation | 98 |
inhibitory effect | 98 |
heart disease | 98 |
data indicate | 98 |
may lead | 98 |
platelet count | 97 |
customer service | 97 |
increased significantly | 97 |
mouse model | 97 |
taken together | 97 |
year old | 96 |
distress syndrome | 96 |
weight gain | 96 |
normal range | 96 |
deficient mice | 96 |
ed patients | 96 |
high dose | 96 |
analysis showed | 95 |
lipid peroxidation | 95 |
cardiovascular disease | 95 |
recent studies | 94 |
hospital stay | 93 |
multivariate analysis | 93 |
treatment group | 93 |
pediatric patients | 92 |
commonly used | 92 |
adverse effects | 92 |
showed significant | 92 |
time points | 92 |
patients presenting | 92 |
adhesion molecule | 92 |
physical activity | 91 |
type ii | 91 |
fold increase | 91 |
iu ml | 91 |
inclusion criteria | 91 |
emergency medicine | 91 |
adverse events | 91 |
type i | 91 |
one year | 91 |
case report | 90 |
cardiovascular risk | 90 |
grass pollen | 89 |
protective effect | 89 |
current study | 89 |
cancer patients | 89 |
cytokine production | 89 |
odds ratio | 89 |
three patients | 89 |
platelet activation | 89 |
first hours | 88 |
also found | 88 |
expression level | 88 |
critical illness | 88 |
wistar rats | 88 |
survival rate | 87 |
obese patients | 87 |
platelet aggregation | 87 |
increased expression | 87 |
differentially expressed | 87 |
per day | 87 |
fold higher | 87 |
high fat | 86 |
plasma glucose | 86 |
cell culture | 86 |
mast cells | 86 |
study included | 85 |
patients showed | 85 |
year period | 85 |
central nervous | 85 |
transgenic mice | 85 |
insulin sensitivity | 84 |
animal model | 84 |
kidney injury | 84 |
serum creatinine | 84 |
dendritic cells | 84 |
first trimester | 84 |
total protein | 84 |
atopic dermatitis | 83 |
lipid profile | 83 |
chain reaction | 83 |
mononuclear cells | 82 |
linear regression | 82 |
significant changes | 82 |
blood cells | 82 |
ffas level | 82 |
results demonstrate | 82 |
ca i | 82 |
previously reported | 82 |
acute myocardial | 82 |
brain injury | 81 |
included patients | 81 |
factors associated | 81 |
activated protein | 81 |
inflammatory responses | 81 |
wide range | 81 |
gel electrophoresis | 81 |
clinical course | 80 |
monoclonal antibodies | 80 |
sectional study | 80 |
statistical significance | 80 |
signaling pathway | 80 |
allergic patients | 80 |
liver injury | 79 |
ed visits | 79 |
replacement therapy | 79 |
nk cells | 79 |
plasma concentrations | 79 |
birth weight | 79 |
study design | 79 |
liver failure | 79 |
blood gases | 79 |
fetal growth | 79 |
liver function | 78 |
lung cancer | 78 |
proinflammatory cytokines | 78 |
dawley rats | 78 |
wound healing | 78 |
signaling pathways | 78 |
polymerase chain | 78 |
ang ii | 78 |
elevated levels | 77 |
may provide | 77 |
portal vein | 77 |
tidal volume | 77 |
rheumatoid arthritis | 77 |
house dust | 77 |
control subjects | 76 |
stem cell | 76 |
five patients | 76 |
mm hg | 76 |
fatty liver | 76 |
liver biopsy | 76 |
control groups | 75 |
negative correlation | 75 |
high level | 75 |
clinical practice | 75 |
average age | 75 |
age years | 75 |
dose dependent | 74 |
immune cells | 74 |
serum albumin | 74 |
protein synthesis | 74 |
total cholesterol | 74 |
family members | 74 |
airway pressure | 74 |
significantly elevated | 74 |
respiratory tract | 73 |
angiotensin ii | 73 |
colorectal cancer | 73 |
hydrogen peroxide | 73 |
preliminary results | 73 |
systolic blood | 73 |
primary outcome | 73 |
electron microscopy | 73 |
prick tests | 72 |
key role | 72 |
protein level | 72 |
immune responses | 72 |
also observed | 72 |
artery disease | 72 |
pao fio | 71 |
gas exchange | 71 |
investigate whether | 71 |
care units | 71 |
three different | 71 |
assessed using | 70 |
ventilated patients | 70 |
significant association | 70 |
confidence interval | 70 |
ct scan | 70 |
prospective observational | 70 |
viral load | 70 |
acute pancreatitis | 70 |
four patients | 70 |
receptor antagonist | 70 |
acute kidney | 70 |
ob gyn | 70 |
low levels | 70 |
significant improvement | 69 |
inflammatory diseases | 69 |
pulmonary vascular | 69 |
time course | 69 |
cell cultures | 69 |
plasma samples | 69 |
fasting glucose | 69 |
hemorrhagic shock | 69 |
respiratory rate | 68 |
monoclonal antibody | 68 |
kidney disease | 68 |
cardiac index | 68 |
controlled trial | 68 |
significantly correlated | 68 |
well known | 68 |
data show | 68 |
positive patients | 68 |
chest pain | 68 |
cell activation | 68 |
prick test | 68 |
may result | 68 |
inflammatory mediators | 68 |
abdominal pain | 67 |
lung function | 67 |
ko mice | 67 |
amniotic fluid | 67 |
blood transfusion | 67 |
sofa score | 67 |
different types | 67 |
university medical | 67 |
vascular endothelial | 67 |
hek cells | 66 |
reperfusion injury | 66 |
healthy individuals | 66 |
binding site | 66 |
cell growth | 66 |
control animals | 66 |
united kingdom | 66 |
day mortality | 66 |
decreased significantly | 66 |
clinical data | 65 |
mean values | 65 |
patients died | 65 |
within days | 65 |
low dose | 65 |
high affinity | 65 |
rat model | 65 |
low molecular | 65 |
surgical patients | 65 |
positively correlated | 65 |
see table | 64 |
systemic inflammatory | 64 |
enzyme activity | 64 |
th day | 64 |
urinary tract | 64 |
serum hbv | 64 |
dust mite | 64 |
acute renal | 64 |
total number | 64 |
oxide synthase | 64 |
ex vivo | 63 |
vascular smooth | 63 |
binding sites | 63 |
growth factors | 63 |
evaluated using | 63 |
positive cells | 63 |
superoxide dismutase | 63 |
even though | 63 |
lymph nodes | 63 |
nephrotic syndrome | 63 |
pilot study | 63 |
disease severity | 63 |
pulmonary embolism | 63 |
glucose metabolism | 62 |
study aimed | 62 |
ige levels | 62 |
major role | 62 |
medical students | 62 |
one hour | 62 |
tertiary care | 62 |
study population | 62 |
clinical trial | 62 |
endothelial dysfunction | 62 |
medical records | 62 |
group compared | 62 |
ejection fraction | 61 |
six patients | 61 |
mast cell | 61 |
lower levels | 61 |
biochemical parameters | 61 |
ovarian cancer | 61 |
total ige | 61 |
hbv infection | 61 |
folic acid | 61 |
red blood | 61 |
studies showed | 61 |
patients underwent | 61 |
patients suffering | 61 |
month period | 61 |
cardiac function | 60 |
log copies | 60 |
prostate cancer | 60 |
investor sentiment | 60 |
study showed | 60 |
liquid chromatography | 60 |
liver tissue | 60 |
renal disease | 60 |
serum samples | 60 |
data demonstrate | 60 |
total rna | 60 |
one week | 60 |
may help | 59 |
severe asthma | 59 |
cell type | 59 |
umbilical vein | 59 |
well tolerated | 59 |
regression model | 59 |
cord uid | 59 |
randomized controlled | 59 |
beneficial effects | 59 |
bl mice | 59 |
doc id | 59 |
tumor cell | 59 |
last years | 59 |
treated patients | 59 |
blood cell | 59 |
treated cells | 58 |
recent years | 58 |
venous pressure | 58 |
multiple sclerosis | 58 |
treatment groups | 58 |
coupled receptors | 58 |
dna repair | 58 |
plasminogen activator | 58 |
age groups | 58 |
lactate levels | 58 |
factor viii | 58 |
target genes | 58 |
preterm birth | 58 |
data analysis | 58 |
density lipoprotein | 57 |
high mortality | 57 |
chronic liver | 57 |
general population | 57 |
new zealand | 57 |
cortisol levels | 57 |
background aims | 57 |
bile acid | 57 |
free radical | 57 |
cell migration | 57 |
higher risk | 57 |
compared using | 57 |
cardiovascular diseases | 57 |
risk assessment | 57 |
family history | 57 |
type mice | 57 |
first days | 56 |
renal transplant | 56 |
fasting blood | 56 |
hcv rna | 56 |
previously shown | 56 |
may represent | 56 |
right ventricular | 56 |
three days | 56 |
inflammatory markers | 56 |
significantly improved | 56 |
medical school | 56 |
investigated whether | 56 |
patient care | 56 |
inflammatory cells | 56 |
chronic disease | 56 |
sample size | 55 |
clinical studies | 55 |
one hundred | 55 |
epithelial cell | 55 |
cytokine levels | 55 |
culture medium | 55 |
biological activity | 55 |
two hours | 55 |
critical role | 55 |
descriptive statistics | 55 |
healthy control | 55 |
study shows | 55 |
vital signs | 54 |
cell count | 54 |
old male | 54 |
food intake | 54 |
high concentrations | 54 |
oxygen consumption | 54 |
glycemic control | 54 |
menstrual cycle | 54 |
insulin levels | 54 |
vitro studies | 54 |
blood mononuclear | 54 |
high prevalence | 54 |
mg day | 54 |
clinically relevant | 54 |
membrane potential | 54 |
standard deviation | 54 |
tract infection | 54 |
gold standard | 54 |
crucial role | 54 |
chb patients | 54 |
kg bw | 54 |
postoperative period | 54 |
renal transplantation | 54 |
transplant recipients | 54 |
higher level | 54 |
blood levels | 53 |
heart surgery | 53 |
data collection | 53 |
time point | 53 |
innate immune | 53 |
hepg cells | 53 |
four groups | 53 |
preterm delivery | 53 |
leading cause | 53 |
demographic data | 53 |
studies suggest | 53 |
similar results | 53 |
cd cells | 53 |
trophoblast cells | 53 |
significant change | 52 |
groups according | 52 |
lung tissue | 52 |
bronchial asthma | 52 |
hospital admission | 52 |
also significantly | 52 |
free radicals | 52 |
way anova | 52 |
dm patients | 52 |
chart review | 52 |
medical university | 52 |
kg body | 52 |
infected patients | 52 |
times higher | 52 |
head injury | 52 |
allergic reactions | 52 |
oral glucose | 52 |
tissue factor | 51 |
diabetic rats | 51 |
prospective cohort | 51 |
poorly understood | 51 |
level i | 51 |
different concentrations | 51 |
clinical signs | 51 |
tolerance test | 51 |
patients may | 51 |
may cause | 51 |
causal closure | 51 |
may explain | 51 |
significantly greater | 51 |
severe acute | 51 |
genes involved | 51 |
cirrhotic patients | 51 |
clinical outcome | 51 |
one month | 51 |
escherichia coli | 51 |
tissue damage | 51 |
th cells | 51 |
human umbilical | 51 |
bile duct | 50 |
energy expenditure | 50 |
male wistar | 50 |
staphylococcus aureus | 50 |
eight patients | 50 |
patients compared | 50 |
patients aged | 50 |
dna binding | 50 |
pharmakologie und | 50 |
levels increased | 50 |
test results | 50 |
dna levels | 50 |
body temperature | 50 |
copd patients | 50 |
early diagnosis | 50 |
group showed | 50 |
chronic inflammation | 50 |
function tests | 50 |
response rate | 50 |
alkaline phosphatase | 50 |
host defense | 50 |
two weeks | 50 |
mrna level | 50 |
exact test | 50 |
bile acids | 50 |
retrospective analysis | 49 |
airway inflammation | 49 |
insulin secretion | 49 |
pivotal role | 49 |
also showed | 49 |
cytotoxic effects | 49 |
mean value | 49 |
dna methylation | 49 |
diastolic blood | 49 |
survival rates | 49 |
knockout mice | 49 |
ischemic stroke | 49 |
fat mass | 49 |
cells showed | 49 |
clinical features | 49 |
dose intravenous | 49 |
toxic effects | 49 |
tumor growth | 49 |
ischemia reperfusion | 48 |
acute lung | 48 |
strand breaks | 48 |
renal replacement | 48 |
one case | 48 |
time rt | 48 |
remains unclear | 48 |
parenteral nutrition | 48 |
age group | 48 |
recommendation iia | 48 |
inflammatory process | 48 |
und toxikologie | 48 |
mean duration | 48 |
results obtained | 48 |
two cases | 48 |
independent risk | 48 |
receptor expression | 48 |
growth restriction | 48 |
seven patients | 48 |
shock patients | 48 |
venous thrombosis | 48 |
connective tissue | 48 |
retrospective cohort | 48 |
future studies | 47 |
chronic renal | 47 |
low concentrations | 47 |
tnf production | 47 |
systemic vascular | 47 |
preterm labor | 47 |
promoter activity | 47 |
white blood | 47 |
pregnant rats | 47 |
treated group | 47 |
general hospital | 47 |
heat shock | 47 |
arachidonic acid | 47 |
growth hormone | 47 |
cell membrane | 47 |
acid sequence | 47 |
control study | 47 |
body fat | 47 |
placebo group | 47 |
nuclear factor | 47 |
blood gas | 47 |
showed significantly | 47 |
selectin expression | 47 |
poor prognosis | 47 |
hemodynamic parameters | 47 |
type diabetic | 47 |
serum alt | 47 |
impaired glucose | 47 |
cord blood | 47 |
combination therapy | 47 |
oxygen delivery | 47 |
first step | 47 |
per patient | 47 |
elderly patients | 47 |
disease progression | 47 |
newly diagnosed | 47 |
jugular vein | 46 |
mechanisms underlying | 46 |
cell survival | 46 |
steady state | 46 |
inhibitory effects | 46 |
icu discharge | 46 |
weeks gestation | 46 |
remained unchanged | 46 |
interquartile range | 46 |
mortality rates | 46 |
may affect | 46 |
saps ii | 46 |
two years | 46 |
hours post | 46 |
within minutes | 46 |
much higher | 46 |
different levels | 46 |
tyrosine kinase | 46 |
severe ards | 46 |
protective effects | 46 |
treated animals | 46 |
significantly less | 46 |
continuous infusion | 46 |
human myometrium | 46 |
binding proteins | 46 |
bronchoalveolar lavage | 46 |
beneficial effect | 46 |
chronic inflammatory | 46 |
spontaneous breathing | 45 |
positive control | 45 |
urine samples | 45 |
hospital discharge | 45 |
normal weight | 45 |
confidence intervals | 45 |
clinical chemistry | 45 |
patients diagnosed | 45 |
portal hypertension | 45 |
time period | 45 |
hours later | 45 |
hbeag negative | 45 |
culture media | 45 |
coupled receptor | 45 |
cardiopulmonary bypass | 45 |
respiratory system | 45 |
exclusion criteria | 45 |
ml vs | 45 |
large number | 45 |
metabolic acidosis | 45 |
thrombin generation | 45 |
per year | 45 |
molecular biology | 45 |
apc resistance | 44 |
pulmonary edema | 44 |
differ significantly | 44 |
also increased | 44 |
central role | 44 |
endotracheal tube | 44 |
blood donors | 44 |
carotid artery | 44 |
also known | 44 |
glucose level | 44 |
cd expression | 44 |
crp levels | 44 |
closely related | 44 |
intervention group | 44 |
high incidence | 44 |
genomic dna | 44 |
well established | 44 |
cerebrospinal fluid | 43 |
cardiac hypertrophy | 43 |
clinical symptoms | 43 |
negative patients | 43 |
higher mortality | 43 |
prothrombin time | 43 |
analysis using | 43 |
red cell | 43 |
information regarding | 43 |
single nucleotide | 43 |
patients developed | 43 |
lipid metabolism | 43 |
mean sd | 43 |
blood cultures | 43 |
acute coronary | 43 |
cells treated | 43 |
roc curve | 43 |
free fatty | 43 |
chronic kidney | 43 |
umbilical cord | 43 |
days post | 43 |
cardiogenic shock | 43 |
lung disease | 42 |
randomly divided | 42 |
negative predictive | 42 |
energy metabolism | 42 |
phase ii | 42 |
less likely | 42 |
surface expression | 42 |
better understanding | 42 |
high doses | 42 |
control mice | 42 |
comet assay | 42 |
converting enzyme | 42 |
treated mice | 42 |
receptor activation | 42 |
possible role | 42 |
laboratory tests | 42 |
children aged | 42 |
hepatic failure | 42 |
group iii | 42 |
care medicine | 42 |
blood vessels | 42 |
enzyme activities | 42 |
infectious diseases | 42 |
postoperative day | 42 |
serum level | 42 |
immunoglobulin therapy | 42 |
data showed | 42 |
pulmonary disease | 42 |
fetal membranes | 42 |
allergic asthma | 42 |
clinical characteristics | 42 |
gram negative | 42 |
cell function | 42 |
enzymatic activity | 42 |
congenital heart | 42 |
ic values | 41 |
pet rabbits | 41 |
promoter region | 41 |
independently associated | 41 |
different time | 41 |
quantum moves | 41 |
receiver operating | 41 |
transforming growth | 41 |
normal human | 41 |
success rate | 41 |
antibiotic therapy | 41 |
findings indicate | 41 |
may indicate | 41 |
urine output | 41 |
potential role | 41 |
decision making | 41 |
colon cancer | 41 |
apoptotic cells | 41 |
vitro model | 41 |
four different | 41 |
significant positive | 41 |
study demonstrates | 41 |
circulating levels | 41 |
therapeutic strategies | 41 |
allergic diseases | 41 |
serum concentrations | 41 |
asthma control | 41 |
inflammatory cytokine | 41 |
pediatric intensive | 41 |
several studies | 41 |
mechanisms involved | 41 |
lower level | 41 |
recombinant protein | 41 |
treated rats | 40 |
internal medicine | 40 |
group received | 40 |
aged years | 40 |
preliminary data | 40 |
dna level | 40 |
reference ranges | 40 |
total body | 40 |
randomly selected | 40 |
acute liver | 40 |
severity score | 40 |
inflammatory processes | 40 |
primary human | 40 |
premature mortality | 40 |
health problem | 40 |
new therapeutic | 40 |
clinical study | 40 |
patients presented | 40 |
small intestine | 40 |
quantitative rt | 40 |
national university | 40 |
first week | 40 |
control cells | 40 |
tissue samples | 40 |
blood volume | 40 |
liver fibrosis | 40 |
specific igg | 40 |
early stage | 40 |
teaching hospital | 40 |
ed visit | 40 |
mitochondrial membrane | 40 |
patients requiring | 40 |
primary care | 40 |
scoring system | 40 |
cesarean section | 40 |
hcv infection | 40 |
expression pattern | 40 |
hbeag positive | 40 |
frequently used | 40 |
hbeag seroconversion | 40 |
short term | 40 |
mg protein | 40 |
obese women | 40 |
confocal microscopy | 40 |
specific antibodies | 40 |
mouse models | 40 |
mental health | 39 |
present work | 39 |
degradation products | 39 |
relative risk | 39 |
three months | 39 |
clinically significant | 39 |
median time | 39 |
surface area | 39 |
blood sample | 39 |
nursing staff | 39 |
may influence | 39 |
mean time | 39 |
autoimmune diseases | 39 |
plasma cortisol | 39 |
ethics committee | 39 |
significant effect | 39 |
cells expressing | 39 |
animal studies | 39 |
statistical difference | 39 |
single dose | 39 |
pressure support | 39 |
probably due | 39 |
previous study | 39 |
days later | 39 |
multiple trauma | 39 |
emergency physicians | 38 |
head trauma | 38 |
antioxidant status | 38 |
fetal brain | 38 |
kidney transplantation | 38 |
six months | 38 |
living cells | 38 |
innate immunity | 38 |
physical examination | 38 |
ige level | 38 |
three times | 38 |
mcg kg | 38 |
medical history | 38 |
research institute | 38 |
united states | 38 |
obese subjects | 38 |
normal saline | 38 |
negative bacteria | 38 |
injury severity | 38 |
high degree | 38 |
vein endothelial | 38 |
previously described | 38 |
increased mortality | 38 |
brain death | 38 |
cytotoxic effect | 38 |
elevated serum | 38 |
significant role | 38 |
control rats | 37 |
endoplasmic reticulum | 37 |
drinking water | 37 |
protein coupled | 37 |
endotracheal intubation | 37 |
positive results | 37 |
may improve | 37 |
square test | 37 |
mammary gland | 37 |
gastrointestinal tract | 37 |
atrial fibrillation | 37 |
among women | 37 |
showed increased | 37 |
trend towards | 37 |
first day | 37 |
human plasma | 37 |
high serum | 37 |
highly expressed | 37 |
food allergies | 37 |
tissue injury | 37 |
important roles | 37 |
therapeutic intervention | 37 |
murine model | 37 |
hcc patients | 37 |
clinical significance | 37 |
computed tomography | 37 |
common cause | 37 |
actin cytoskeleton | 37 |
major cause | 37 |
ards patients | 37 |
flow rate | 37 |
liver diseases | 37 |
xanthine oxidase | 37 |
tract infections | 37 |
major surgery | 37 |
nine patients | 37 |
prognostic value | 37 |
endothelial growth | 37 |
overall mortality | 37 |
low level | 37 |
hospital cardiac | 37 |
women undergoing | 37 |
sepsis syndrome | 37 |
ten patients | 37 |
analysed using | 37 |
related genes | 37 |
university school | 37 |
new york | 37 |
flow cytometric | 37 |
quantitative real | 37 |
follicular fluid | 37 |
clinical use | 36 |
patient groups | 36 |
normal values | 36 |
marked increase | 36 |
study investigated | 36 |
calculated using | 36 |
leptin levels | 36 |
normal controls | 36 |
organ damage | 36 |
postmenopausal women | 36 |
intracellular ca | 36 |
human skin | 36 |
skin tests | 36 |
considered significant | 36 |
white cell | 36 |
hela cells | 36 |
renal biopsy | 36 |
alert level | 36 |
tissue oxygenation | 36 |
group consisted | 36 |
serum il | 36 |
also performed | 36 |
nutritional support | 36 |
food allergens | 36 |
severe head | 36 |
male rats | 36 |
high ffas | 36 |
higher concentrations | 36 |
milk allergy | 36 |
cervical ripening | 36 |
small number | 35 |
better understand | 35 |
liver enzymes | 35 |
high glucose | 35 |
coagulation factors | 35 |
retrospective review | 35 |
provocation test | 35 |
birch pollen | 35 |
inhibitory activity | 35 |
jugular bulb | 35 |
female mice | 35 |
significant increases | 35 |
consecutive days | 35 |
glomerular filtration | 35 |
abdominal obesity | 35 |
disease activity | 35 |
showed higher | 35 |
laboratory data | 35 |
clinical outcomes | 35 |
population exposure | 35 |
mainly due | 35 |
alertness level | 35 |
early stages | 35 |
levels may | 35 |
environmental factors | 35 |
broad spectrum | 35 |
data collected | 35 |
tumor suppressor | 35 |
study aims | 35 |
randomly assigned | 35 |
important factor | 35 |
class ii | 35 |
studied patients | 35 |
experimental model | 35 |
high frequency | 35 |
blood culture | 35 |
collected data | 35 |
data obtained | 35 |
protective role | 35 |
asthma symptoms | 35 |
vein thrombosis | 35 |
nadph oxidase | 35 |
alt levels | 35 |
morphological changes | 34 |
stress response | 34 |
first study | 34 |
also measured | 34 |
old female | 34 |
overall survival | 34 |
different doses | 34 |
glasgow coma | 34 |
hcc cell | 34 |
years ago | 34 |
transit disruptions | 34 |
using elisa | 34 |
matched controls | 34 |
surgical procedures | 34 |
platelet counts | 34 |
complement activation | 34 |
virus infection | 34 |
immune function | 34 |
linked immunosorbent | 34 |
fio ratio | 34 |
antioxidant capacity | 34 |
map kinase | 34 |
diagnostic criteria | 34 |
high blood | 34 |
significantly inhibited | 34 |
acid residues | 34 |
glucose uptake | 34 |
graft survival | 34 |
artery bypass | 34 |
filtration rate | 34 |
reporter gene | 34 |
antioxidant activity | 34 |
mesenchymal stem | 34 |
hepatic fibrosis | 34 |
study groups | 34 |
drug resistance | 34 |
ae years | 34 |
higher rates | 34 |
potential therapeutic | 34 |
chronic diseases | 34 |
first group | 34 |
genes encoding | 33 |
total serum | 33 |
age range | 33 |
statistically different | 33 |
studies using | 33 |
elisa kits | 33 |
airway management | 33 |
immunosorbent assay | 33 |
burn injury | 33 |
enteral nutrition | 33 |
cell differentiation | 33 |
blood coagulation | 33 |
old woman | 33 |
hdl cholesterol | 33 |
correlation coefficient | 33 |
may occur | 33 |
beta cells | 33 |
patients required | 33 |
chronic hbv | 33 |
granulosa cells | 33 |
cytokine release | 33 |
fasting plasma | 33 |
takes place | 33 |
tandem mass | 33 |
study suggests | 33 |
early pregnancy | 33 |
operating characteristic | 33 |
abdominal surgery | 33 |
increasing concentrations | 33 |
positive predictive | 33 |
demographic characteristics | 33 |
response syndrome | 33 |
differential expression | 33 |
kg i | 33 |
glutathione peroxidase | 33 |
human lung | 33 |
model system | 33 |
ad libitum | 33 |
low density | 33 |
selectin gene | 33 |
dose response | 33 |
kg hr | 33 |
estrogen receptor | 33 |
rat liver | 33 |
pollen season | 33 |
specific immunotherapy | 33 |
acute rejection | 33 |
mtt assay | 33 |
cultured human | 33 |
rat brain | 33 |
bacterial infections | 33 |
brain barrier | 33 |
graft function | 33 |
blood count | 33 |
vascular endothelium | 32 |
case reports | 32 |
deep learning | 32 |
following treatment | 32 |
therapeutic effect | 32 |
ed physicians | 32 |
serum neopterin | 32 |
nutritional status | 32 |
bariatric surgery | 32 |
wide variety | 32 |
male patients | 32 |
von willebrand | 32 |
also investigated | 32 |
arterial hypertension | 32 |
may serve | 32 |
receive either | 32 |
stromal cells | 32 |
expression profiles | 32 |
inflammatory disease | 32 |
alertness levels | 32 |
igg levels | 32 |
phase i | 32 |
viral infection | 32 |
septic complications | 32 |
recommendation iib | 32 |
cell membranes | 32 |
fluorescence microscopy | 32 |
secondary analysis | 32 |
carcinoma cells | 32 |
asthmatic patients | 32 |
results support | 32 |
will provide | 32 |
two days | 32 |
serum concentration | 32 |
adrenergic receptor | 32 |
apoptotic cell | 32 |
conducted using | 32 |
surgical icu | 32 |
animal experiments | 32 |
serum calcium | 32 |
levels decreased | 32 |
general anesthesia | 32 |
renal allograft | 32 |
soluble adhesion | 32 |
mitochondrial dysfunction | 32 |
laboratory parameters | 32 |
gastric bypass | 32 |
per se | 32 |
regression models | 32 |
provide evidence | 32 |
ivig may | 32 |
intravenous immunoglobulins | 32 |
stage renal | 32 |
oxidative damage | 32 |
portal venous | 32 |
artery catheter | 32 |
mammalian cells | 32 |
mice showed | 32 |
chronic obstructive | 32 |
controlled study | 32 |
blood lactate | 32 |
gene transcription | 31 |
seven days | 31 |
matrix metalloproteinases | 31 |
recently shown | 31 |
viral infections | 31 |
thermal injury | 31 |
correlated well | 31 |
iga nephropathy | 31 |
induced apoptosis | 31 |
outcome measures | 31 |
morbidly obese | 31 |
blood sampling | 31 |
inflammatory effects | 31 |
study using | 31 |
respiratory symptoms | 31 |
plasma concentration | 31 |
intercellular adhesion | 31 |
per group | 31 |
dna synthesis | 31 |
increased blood | 31 |
ill children | 31 |
progenitor cells | 31 |
evidence suggests | 31 |
time dependent | 31 |
trauma center | 31 |
secondary outcomes | 31 |
stroke volume | 31 |
creatinine ratio | 31 |
per week | 31 |
study conducted | 31 |
cells compared | 31 |
renal tubular | 31 |
every day | 31 |
first year | 31 |
therapeutic approaches | 31 |
control patients | 31 |
poor outcome | 31 |
data suggests | 31 |
chronic urticaria | 31 |
induced dna | 31 |
peanut allergy | 31 |
host response | 31 |
nmda receptor | 31 |
observation period | 31 |
mice lacking | 31 |
complement system | 31 |
mixed venous | 31 |
effective treatment | 31 |
model group | 31 |
artery pressure | 31 |
enteral feeding | 31 |
fluid resuscitation | 31 |
healthy children | 31 |
virologic response | 31 |
convenience sample | 31 |
total antioxidant | 30 |
prospectively studied | 30 |
ventilatory support | 30 |
body composition | 30 |
orthotopic liver | 30 |
surgery patients | 30 |
glucose homeostasis | 30 |
significant negative | 30 |
relatively low | 30 |
cardiovascular events | 30 |
two types | 30 |
alanine aminotransferase | 30 |
community area | 30 |
ion channels | 30 |
asthma patients | 30 |
level classification | 30 |
human health | 30 |
challenge test | 30 |
highly significant | 30 |
quantified using | 30 |
novel therapeutic | 30 |
cell carcinoma | 30 |
disseminated intravascular | 30 |
intravascular coagulation | 30 |
acid composition | 30 |
bleeding complications | 30 |
early detection | 30 |
may increase | 30 |
polycystic ovary | 30 |
natural killer | 30 |
assess whether | 30 |
quantitative analysis | 30 |
play important | 30 |
gene promoter | 30 |
peritoneal macrophages | 30 |
protein kinases | 30 |
selectin levels | 30 |
human endometrial | 30 |
hyaluronic acid | 30 |
sentiment index | 30 |
mean serum | 30 |
recombinant human | 30 |
right ventricle | 30 |
willebrand factor | 30 |
inverse correlation | 30 |
therapeutic agents | 30 |
human keratinocytes | 30 |
may reflect | 30 |
repeated measures | 30 |
also demonstrated | 30 |
allergic reaction | 30 |
allergic inflammation | 30 |
results will | 30 |
cholesterol levels | 30 |
blood collection | 30 |
femoral artery | 30 |
oral administration | 30 |
traumatic brain | 30 |
rank test | 30 |
increased serum | 30 |
th percentile | 30 |
lower respiratory | 30 |
performance liquid | 30 |
urinary protein | 30 |
major risk | 30 |
vivo studies | 30 |
renal dysfunction | 30 |
skin lesions | 30 |
blood urea | 30 |
emergency departments | 30 |
adverse reactions | 30 |
differential diagnosis | 30 |
hepatic dysfunction | 29 |
brain tissue | 29 |
old boy | 29 |
using specific | 29 |
false positive | 29 |
higher percentage | 29 |
vascular tone | 29 |
different cell | 29 |
terminal domain | 29 |
molecular level | 29 |
retrospective chart | 29 |
results demonstrated | 29 |
normal pregnancy | 29 |
fetal plasma | 29 |
pcr analysis | 29 |
risk patients | 29 |
studies revealed | 29 |
relatively high | 29 |
fusion protein | 29 |
might contribute | 29 |
molecular mechanism | 29 |
univariate analysis | 29 |
edema formation | 29 |
inflammatory reaction | 29 |
dental disease | 29 |
biological systems | 29 |
statistically significantly | 29 |
obstructive pulmonary | 29 |
creatinine clearance | 29 |
odds ratios | 29 |
skin test | 29 |
stimulating factor | 29 |
multivariable logistic | 29 |
receptor binding | 29 |
maternal age | 29 |
surgical treatment | 29 |
dna adducts | 29 |
hepatic arterial | 29 |
written informed | 29 |
decreased expression | 29 |
also reduced | 29 |
pseudomonas aeruginosa | 29 |
liver cancer | 29 |
respiratory syndrome | 29 |
gestational diabetes | 29 |
dependent increase | 29 |
autoimmune disease | 29 |
reduced expression | 29 |
high sensitivity | 29 |
wt mice | 29 |
clotting time | 29 |
neurodegenerative diseases | 29 |
response element | 29 |
blood products | 29 |
world health | 29 |
also studied | 29 |
colon carcinoma | 29 |
active site | 29 |
higher incidence | 29 |
following trauma | 29 |
dependent protein | 29 |
cell responses | 29 |
second group | 29 |
increased compared | 29 |
signalling pathways | 29 |
eoc cells | 29 |
vena cava | 29 |
also determined | 29 |
serum leptin | 29 |
contact dermatitis | 29 |
tg mice | 29 |
prospectively collected | 29 |
naturally occurring | 28 |
human placenta | 28 |
i trauma | 28 |
decidual cells | 28 |
organ injury | 28 |
treg cells | 28 |
different groups | 28 |
antithrombin iii | 28 |
using different | 28 |
human endometrium | 28 |
old man | 28 |
multivariate logistic | 28 |
patients whose | 28 |
samples obtained | 28 |
also used | 28 |
immune activation | 28 |
four times | 28 |
treatment period | 28 |
nocturnal enuresis | 28 |
cardiac fibroblasts | 28 |
drug development | 28 |
brain regions | 28 |
whole genome | 28 |
cell counts | 28 |
emergency room | 28 |
group patients | 28 |
adverse effect | 28 |
preventive behaviours | 28 |
congestive heart | 28 |
induced changes | 28 |
renal insufficiency | 28 |
coma scale | 28 |
take place | 28 |
liver damage | 28 |
cerebral blood | 28 |
time spent | 28 |
social systems | 28 |
baseline characteristics | 28 |
binding activity | 28 |
plasma leptin | 28 |
human serum | 28 |
inflammatory bowel | 28 |
experimental animals | 28 |
leydig cells | 28 |
life support | 28 |
affinity chromatography | 28 |
i levels | 28 |
sequence analysis | 28 |
proinflammatory cytokine | 28 |
ug ml | 28 |
cell population | 28 |
baseline values | 28 |
chief complaint | 28 |
underlying disease | 28 |
treatment option | 28 |
term follow | 28 |
many patients | 28 |
medical intensive | 28 |
maternal plasma | 28 |
took place | 28 |
phosphorylation sites | 28 |
secretory phase | 28 |
using standard | 27 |
mean difference | 27 |
medical care | 27 |
pulmonary function | 27 |
sequence homology | 27 |
significant higher | 27 |
sepsis patients | 27 |
new cases | 27 |
strongly associated | 27 |
recommendation i | 27 |
classification network | 27 |
cortisol production | 27 |
situ hybridization | 27 |
thromboplastin time | 27 |
cells may | 27 |
primary endpoint | 27 |
per hour | 27 |
ct scans | 27 |
villous explants | 27 |
bovine serum | 27 |
immune cell | 27 |
markedly increased | 27 |
group without | 27 |
patient group | 27 |
patients using | 27 |
peritoneal cavity | 27 |
study provides | 27 |
oxygen tension | 27 |
ige binding | 27 |
blood serum | 27 |
alt normalization | 27 |
past years | 27 |
evaluate whether | 27 |
polyclonal antibodies | 27 |
peritoneal dialysis | 27 |
obese children | 27 |
soluble fibrin | 27 |
lavage fluid | 27 |
vascular permeability | 27 |
investigated using | 27 |
celiac disease | 27 |
cancer stem | 27 |
may reduce | 27 |
drug administration | 27 |
chemokine receptor | 27 |
independent predictors | 27 |
hepatic artery | 27 |
increased il | 27 |
pain management | 27 |
metabolic control | 27 |
immunohistochemical analysis | 27 |
dna double | 27 |
patient outcomes | 27 |
low serum | 27 |
diabetic subjects | 27 |
blood transfusions | 27 |
therapeutic hypothermia | 27 |
kinase inhibitor | 27 |
high density | 27 |
leukocyte adhesion | 27 |
stage i | 27 |
positive blood | 27 |
carbon dioxide | 27 |
urea nitrogen | 27 |
liver tissues | 27 |
expressed genes | 27 |
energy transfer | 27 |
receptor potential | 27 |
serum total | 27 |
acid levels | 27 |
survival time | 27 |
bacterial translocation | 27 |
natriuretic peptide | 27 |
ovary syndrome | 27 |
cellular processes | 27 |
single cell | 27 |
therapeutic approach | 27 |
transient receptor | 27 |
hiv infection | 27 |
like growth | 27 |
persistent pulmonary | 27 |
mass spectrometer | 27 |
inflammatory conditions | 27 |
young adults | 27 |
deep vein | 27 |
steroid hormones | 27 |
pathological conditions | 27 |
intravenous administration | 27 |
rats received | 27 |
patient safety | 27 |
bacterial infection | 27 |
research center | 27 |
blood sugar | 27 |
care patients | 27 |
clinical relevance | 27 |
inotropic support | 27 |
molecular mass | 27 |
also evaluated | 27 |
second messenger | 27 |
cellular uptake | 27 |
biologically active | 27 |
lupus erythematosus | 27 |
guinea pig | 27 |
levels compared | 27 |
plasma volume | 27 |
still unknown | 26 |
antiviral therapy | 26 |
multiple logistic | 26 |
identified using | 26 |
postoperative complications | 26 |
border restrictions | 26 |
neurological outcome | 26 |
low hdl | 26 |
results indicated | 26 |
table shows | 26 |
clinical efficacy | 26 |
ventricular function | 26 |
serine protease | 26 |
following parameters | 26 |
fetal weight | 26 |
severe respiratory | 26 |
medical treatment | 26 |
luciferase reporter | 26 |
service level | 26 |
serum ige | 26 |
nitrogen balance | 26 |
statistical differences | 26 |
wilcoxon rank | 26 |
correlation coefficients | 26 |
nucleotide polymorphisms | 26 |
patients following | 26 |
months post | 26 |
ae vs | 26 |
significantly enhanced | 26 |
laboratory findings | 26 |
fasting insulin | 26 |
higher rate | 26 |
prone position | 26 |
drug delivery | 26 |
available elisa | 26 |
done using | 26 |
minute ventilation | 26 |
adefovir dipivoxil | 26 |
severity scores | 26 |
fresh frozen | 26 |
icu mortality | 26 |
chronic pain | 26 |
surface receptors | 26 |
oxygen radicals | 26 |
might play | 26 |
expression analysis | 26 |
pulmonary arterial | 26 |
acid transport | 26 |
low risk | 26 |
neuronal cells | 26 |
human liver | 26 |
mean blood | 26 |
studies will | 26 |
essential role | 26 |
largely unknown | 26 |
shear stress | 26 |
expression patterns | 26 |
trpc channels | 26 |
lymph node | 26 |
sprague dawley | 26 |
hydrocortisone therapy | 26 |
experimental group | 26 |
pain scores | 26 |
adult respiratory | 26 |
useful tool | 26 |
highly sensitive | 26 |
generalized anxiety | 26 |
fetal sheep | 26 |
remaining patients | 26 |
admitted patients | 26 |
facs analysis | 26 |
studies show | 26 |
coronary angiography | 26 |
respiratory disease | 26 |
increasing evidence | 26 |
studies indicate | 26 |
dendritic cell | 26 |
cross sectional | 25 |
platelet function | 25 |
will also | 25 |
nafld patients | 25 |
decreased levels | 25 |
hepatic function | 25 |
angiotensin converting | 25 |
viral hepatitis | 25 |
asthmatic children | 25 |
hemodynamic changes | 25 |
test whether | 25 |
differed significantly | 25 |
two major | 25 |
clinical decision | 25 |
fold lower | 25 |
using two | 25 |
supine position | 25 |
normal pregnancies | 25 |
onset preeclampsia | 25 |
change significantly | 25 |
induced il | 25 |
intrauterine growth | 25 |
medical record | 25 |
hepatic encephalopathy | 25 |
emergency medical | 25 |
healthy donors | 25 |
cortisol concentrations | 25 |
end stage | 25 |
findings may | 25 |
endothelial function | 25 |
full length | 25 |
enrolled patients | 25 |
male sprague | 25 |
cancer therapy | 25 |
pregnancy outcome | 25 |
target gene | 25 |
proteins involved | 25 |
human myometrial | 25 |
protein content | 25 |
mesangial cells | 25 |
patient population | 25 |
expression may | 25 |
cell transformation | 25 |
academic ed | 25 |
four weeks | 25 |
gene polymorphism | 25 |
hours following | 25 |
scanning electron | 25 |
cerebral ischemia | 25 |
hepatic blood | 25 |
collagen type | 25 |
oleic acid | 25 |
directed mutagenesis | 25 |
vitro assays | 25 |
protein complexes | 25 |
bowel disease | 25 |
stably transfected | 25 |
clinical history | 25 |
paraffin embedded | 25 |
colony formation | 25 |
patient characteristics | 25 |
therapeutic target | 25 |
medical centre | 25 |
will allow | 25 |
clinical examination | 25 |
myocardial ischemia | 25 |
fetal lung | 25 |
science foundation | 25 |
clinical manifestations | 25 |
studies demonstrated | 25 |
guinea pigs | 25 |
elisa method | 25 |
different stages | 25 |
pollen allergy | 25 |
free amino | 25 |
women without | 25 |
intracranial pressure | 25 |
show significant | 25 |
cancer risk | 25 |
white matter | 25 |
levels within | 25 |
mice compared | 25 |
treatment response | 25 |
good correlation | 25 |
proteolytic activity | 25 |
magnetic stimulation | 25 |
without affecting | 25 |
least two | 25 |
normal control | 25 |
factor vii | 25 |
likert scale | 25 |
ros production | 25 |
also present | 25 |
emergency care | 25 |
mean sem | 25 |
results revealed | 25 |
multiple regression | 25 |
like receptors | 25 |
descriptive study | 25 |
mda levels | 25 |
receptor mrna | 24 |
serum glucose | 24 |
visceral fat | 24 |
internal jugular | 24 |
pg kg | 24 |
activation markers | 24 |
ml respectively | 24 |
surgical procedure | 24 |
clinical parameters | 24 |
two main | 24 |
patient satisfaction | 24 |
inflammatory effect | 24 |
obtained results | 24 |
room temperature | 24 |
cell infiltration | 24 |
showed similar | 24 |
nude mice | 24 |
also shown | 24 |
anhepatic stage | 24 |
studied using | 24 |
serum insulin | 24 |
three years | 24 |
whitney test | 24 |
using flow | 24 |
physiological conditions | 24 |
apache iii | 24 |
lactate dehydrogenase | 24 |
eligible patients | 24 |
severe trauma | 24 |
trophoblast cell | 24 |
bypass grafting | 24 |
epidemiological studies | 24 |
egg white | 24 |
urinary neopterin | 24 |
many studies | 24 |
strong correlation | 24 |
five years | 24 |
human blood | 24 |
systemic inflammation | 24 |
transcriptional regulation | 24 |
mean score | 24 |
expression profile | 24 |
insulin resistant | 24 |
lps challenge | 24 |
case series | 24 |
stock market | 24 |
vascular disease | 24 |
lymphocyte ratio | 24 |
positive effect | 24 |
four days | 24 |
drug allergy | 24 |
transduction pathways | 24 |
high grade | 24 |
clinical improvement | 24 |
cultured cells | 24 |
factor alpha | 24 |
underlying mechanisms | 24 |
data provide | 24 |
reverse transcription | 24 |
thrombolytic therapy | 24 |
total bilirubin | 24 |
cells express | 24 |
volatility index | 24 |
using real | 24 |
ige reactivity | 24 |
human endothelial | 24 |
expression vector | 24 |
increasing doses | 24 |
months later | 24 |
signalling pathway | 24 |
systemic lupus | 24 |
placental tissue | 24 |
programmed cell | 24 |
curriculum development | 24 |
higher doses | 24 |
jak stat | 24 |
undergoing elective | 24 |
single center | 24 |
pathway analysis | 24 |
double strand | 24 |
next step | 24 |
first three | 24 |
pediatric emergency | 24 |
gene regulation | 24 |
normal subjects | 24 |
completely abolished | 24 |
therapeutic potential | 24 |
training program | 24 |
tubular epithelial | 24 |
endothelial activation | 24 |
obstetrics gynecology | 24 |
vitro experiments | 24 |
within normal | 24 |
two times | 24 |
published data | 24 |
health status | 24 |
lesser extent | 24 |
like receptor | 24 |
data support | 24 |
retinoic acid | 24 |
normal alt | 24 |
elective surgery | 24 |
two studies | 24 |
month follow | 24 |
examined whether | 24 |
therapeutic targets | 24 |
inflammatory activity | 24 |
medical college | 24 |
monocytes macrophages | 24 |
central obesity | 24 |
late gestation | 24 |
rats fed | 24 |
resource utilization | 24 |
correlation analysis | 24 |
young children | 24 |
miu ml | 24 |
alternative splicing | 24 |
class i | 24 |
higher prevalence | 24 |
independent predictor | 24 |
inversely correlated | 24 |
old girl | 24 |
early phase | 24 |
cells using | 24 |
matrix proteins | 24 |
study demonstrated | 24 |
normal levels | 24 |
alcoholic fatty | 23 |
phase proteins | 23 |
analysis indicated | 23 |
cerebral oxygenation | 23 |
cellular level | 23 |
newborn offspring | 23 |
fulminant hepatic | 23 |
months old | 23 |
antimicrobial activity | 23 |
hazard ratio | 23 |
organ system | 23 |
female rats | 23 |
ligand binding | 23 |
present results | 23 |
point mutation | 23 |
kinase activity | 23 |
underlying mechanism | 23 |
body surface | 23 |
health organization | 23 |
elisa kit | 23 |
intravenous injection | 23 |
multiple linear | 23 |
fluid balance | 23 |
academic medical | 23 |
one hand | 23 |
capillary permeability | 23 |
non invasive | 23 |
ridesourcing demand | 23 |
recent data | 23 |
sum test | 23 |
one group | 23 |
well characterized | 23 |
cell lysates | 23 |
possible mechanism | 23 |
epidermal growth | 23 |
method using | 23 |
selected patients | 23 |
ace activity | 23 |
every min | 23 |
receptor agonist | 23 |
increased plasma | 23 |
adiponectin levels | 23 |
within one | 23 |
randomized study | 23 |
right atrial | 23 |
time periods | 23 |
intracranial hypertension | 23 |
soft tissue | 23 |
model assessment | 23 |
thrombus formation | 23 |
aea levels | 23 |
gnrh ii | 23 |
health sciences | 23 |
activator inhibitor | 23 |
ca influx | 23 |
triglyceride levels | 23 |
every hours | 23 |
immunoglobulin treatment | 23 |
previous reports | 23 |
polyacrylamide gel | 23 |
recent study | 23 |
neutrophil infiltration | 23 |
low doses | 23 |
controlled trials | 23 |
parathyroid hormone | 23 |
image analysis | 23 |
i min | 23 |
partial thromboplastin | 23 |
metabolic disorders | 23 |
open reading | 23 |
study indicates | 23 |
prognostic factors | 23 |
results suggested | 23 |
developmental stages | 23 |
ng kg | 23 |
ventricular ejection | 23 |
patch test | 23 |
chronic heart | 23 |
markedly reduced | 23 |
human neutrophils | 23 |
immune globulin | 23 |
bacterial growth | 23 |
within months | 23 |
adverse drug | 23 |
venous catheter | 23 |
cycle arrest | 23 |
higher values | 23 |
experimental conditions | 23 |
respiratory insufficiency | 23 |
hypertensive patients | 23 |
herpes simplex | 23 |
one third | 23 |
research group | 23 |
highly conserved | 23 |
risk stratification | 23 |
nan title | 23 |
squamous cell | 23 |
host cells | 23 |
liver cells | 23 |
cigarette smoke | 23 |
target cells | 23 |
previously demonstrated | 23 |
successful treatment | 23 |
concentration range | 23 |
experimental models | 23 |
negative sepsis | 23 |
cerebral cortex | 23 |
abdominal sepsis | 23 |
classified according | 23 |
also associated | 23 |
obtained using | 22 |
biological activities | 22 |
camp levels | 22 |
hours prior | 22 |
diabetic mice | 22 |
neuropathic pain | 22 |
allele frequencies | 22 |
caloric intake | 22 |
mean pulmonary | 22 |
induced activation | 22 |
cgmp signaling | 22 |
high expression | 22 |
diagnostic accuracy | 22 |
endotoxic shock | 22 |
ic value | 22 |
dust mites | 22 |
less sensitive | 22 |
bile ducts | 22 |
infection control | 22 |
cardiac failure | 22 |
adult male | 22 |
resistance index | 22 |
lps injection | 22 |
main cause | 22 |
free cortisol | 22 |
high resolution | 22 |
adverse event | 22 |
first two | 22 |
cox regression | 22 |
calcium levels | 22 |
well understood | 22 |
one day | 22 |
extracorporeal circulation | 22 |
treatment failure | 22 |
patient demographics | 22 |
preterm infants | 22 |
induced cell | 22 |
recently identified | 22 |
last months | 22 |
reported cases | 22 |
fold increased | 22 |
regarding covid | 22 |
molecular basis | 22 |
cecal ligation | 22 |
median duration | 22 |
considered statistically | 22 |
resonance energy | 22 |
study suggest | 22 |
detected using | 22 |
detection limit | 22 |
early onset | 22 |
inflammatory properties | 22 |
laser desorption | 22 |
uncontrolled asthma | 22 |
hypersensitivity reactions | 22 |
calcium channel | 22 |
curve analysis | 22 |
two methods | 22 |
much lower | 22 |
transcriptional level | 22 |
tissue sections | 22 |
vs control | 22 |
reference range | 22 |
clostridium difficile | 22 |
study investigates | 22 |
cell apoptosis | 22 |
expressing cells | 22 |
data regarding | 22 |
coagulation system | 22 |
international cases | 22 |
receptor antagonists | 22 |
levels correlated | 22 |
histological examination | 22 |
brain damage | 22 |
lipoprotein cholesterol | 22 |
bypass surgery | 22 |
right heart | 22 |
dna strand | 22 |
significant impact | 22 |
common sentiment | 22 |
risk group | 22 |
vitro study | 22 |
membrane protein | 22 |
cancer treatment | 22 |
quality control | 22 |
adverse outcomes | 22 |
cytometric analysis | 22 |
respiratory mechanics | 22 |
well documented | 22 |
inflammatory cell | 22 |
life span | 22 |
pressure monitoring | 22 |
whole body | 22 |
insulin signaling | 22 |
days following | 22 |
lactation period | 22 |
diabetic nephropathy | 22 |
inspiratory pressure | 22 |
candidate genes | 22 |
serum lactate | 22 |
base excess | 22 |
patient presented | 22 |
mice fed | 22 |
side effect | 22 |
mean follow | 22 |
new insights | 22 |
experimental groups | 22 |
mean ae | 22 |
alt level | 22 |
barrier function | 22 |
complex i | 22 |
cell damage | 22 |
metabolic risk | 22 |
rats treated | 22 |
asthma exacerbation | 22 |
protease inhibitors | 22 |
using high | 22 |
chi square | 22 |
less pronounced | 22 |
potent inhibitor | 22 |
infectious disease | 22 |
differentially regulated | 22 |
cdna library | 22 |
renal injury | 22 |
experimental study | 22 |
ischemic heart | 22 |
statistical analyses | 22 |
autologous blood | 22 |
allergen immunotherapy | 22 |
ischemic injury | 22 |
fusion proteins | 22 |
mcg ml | 22 |
high pressure | 21 |
uterine emg | 21 |
tail vein | 21 |
clinical laboratory | 21 |
dependent inhibition | 21 |
hospitalized patients | 21 |
liver transplant | 21 |
high performance | 21 |
neonatal outcome | 21 |
magnetic resonance | 21 |
small molecules | 21 |
infectious complications | 21 |
found significantly | 21 |
cationic amino | 21 |
deleterious effects | 21 |
despite enhanced | 21 |
binding domain | 21 |
pcr products | 21 |
tidal volumes | 21 |
silver nanoparticles | 21 |
vitro methods | 21 |
angiogenic factors | 21 |
damage response | 21 |
total cost | 21 |
first episode | 21 |
results provide | 21 |
stimulating hormone | 21 |
mass spectrometric | 21 |
alcohol consumption | 21 |
transit time | 21 |
test system | 21 |
rater reliability | 21 |
additional information | 21 |
coagulation factor | 21 |
creatine kinase | 21 |
organ donation | 21 |
upper airway | 21 |
higher serum | 21 |
induced platelet | 21 |
tree pollen | 21 |
older age | 21 |
medical sciences | 21 |
term outcome | 21 |
healthy women | 21 |
tissue hypoxia | 21 |
small cell | 21 |
negatively correlated | 21 |
reading frame | 21 |
glucose concentration | 21 |
nmol mg | 21 |
showed high | 21 |
northern blot | 21 |
negative controls | 21 |
shed blood | 21 |
end products | 21 |
increased incidence | 21 |
might also | 21 |
reduced glutathione | 21 |
experiments revealed | 21 |
pediatric nephrology | 21 |
light microscopy | 21 |
liver regeneration | 21 |
specific expression | 21 |
year follow | 21 |
groups showed | 21 |
serum protein | 21 |
acid use | 21 |
beta cell | 21 |
long time | 21 |
clinical diagnosis | 21 |
induced oxidative | 21 |
assay using | 21 |
specific antibody | 21 |
data sets | 21 |
arrest patients | 21 |
allograft recipients | 21 |
new method | 21 |
dna samples | 21 |
also assessed | 21 |
pcr amplification | 21 |
acid metabolism | 21 |
angiotensin system | 21 |
received either | 21 |
hoc analysis | 21 |
using spss | 21 |
patients included | 21 |
psychological stress | 21 |
injured patients | 21 |
among children | 21 |
pleural effusion | 21 |
surgical intervention | 21 |
age matched | 21 |
five days | 21 |
metabolic abnormalities | 21 |
gas analysis | 21 |
may therefore | 21 |
negative control | 21 |
transcript levels | 21 |
cell populations | 21 |
fully understood | 21 |
prospective randomized | 21 |
higher among | 21 |
grade iii | 21 |
tested whether | 21 |
future research | 21 |
continuous variables | 21 |
melanoma cells | 21 |
endothelial damage | 21 |
lung compliance | 21 |
mortality risk | 21 |
surface antigen | 21 |
induced liver | 21 |
retrospectively reviewed | 21 |
recently developed | 21 |
positive rate | 21 |
observations suggest | 21 |
cardiac myocytes | 21 |
advanced glycation | 21 |
ml lps | 21 |
coronavirus disease | 21 |
remained stable | 21 |
cerebral artery | 21 |
least hours | 21 |
calcium concentrations | 21 |
pregnancies complicated | 21 |
transcriptional activation | 21 |
caesarean section | 21 |
downward causation | 21 |
many different | 21 |
carbohydrate metabolism | 21 |
supply chain | 21 |
spontaneous circulation | 21 |
pelvic organ | 21 |
albumin levels | 21 |
previously published | 21 |
mean total | 21 |
preliminary study | 21 |
examine whether | 21 |
granulosa cell | 21 |
lps induced | 21 |
acute inflammatory | 21 |
findings show | 21 |
intraperitoneal injection | 21 |
frozen plasma | 21 |
wedge pressure | 21 |
animal testing | 21 |
inos expression | 21 |
hong kong | 21 |
also decreased | 21 |
nucleic acids | 21 |
pcr using | 20 |
term effects | 20 |
platelet surface | 20 |
cell mediated | 20 |
tree nut | 20 |
russian science | 20 |
dimensional gel | 20 |
one study | 20 |
results may | 20 |
treatment significantly | 20 |
rank sum | 20 |
treatment may | 20 |
macrophage activation | 20 |
large numbers | 20 |
dependent variable | 20 |
quality improvement | 20 |
head ct | 20 |
therapeutic strategy | 20 |
human fetal | 20 |
inferior vena | 20 |
significant correlations | 20 |
great importance | 20 |
lipid peroxide | 20 |
allele frequency | 20 |
positively associated | 20 |
new approach | 20 |
serum cholesterol | 20 |
leading causes | 20 |
adult rats | 20 |
open heart | 20 |
late onset | 20 |
patients suffered | 20 |
ventricular fibrillation | 20 |
two independent | 20 |
physiological functions | 20 |
also examined | 20 |
kda protein | 20 |
desorption ionization | 20 |
joint inflammation | 20 |
lung inflammation | 20 |
apoptotic effects | 20 |
mean body | 20 |
attending physician | 20 |
metabolic alterations | 20 |
pancreatic beta | 20 |
yrd region | 20 |
adaptive immunity | 20 |
significant risk | 20 |
study will | 20 |
plasma exchange | 20 |
meconium passage | 20 |
increasing number | 20 |
glioma cells | 20 |
without significant | 20 |
left ventricle | 20 |
opioid receptor | 20 |
related changes | 20 |
among others | 20 |
higher compared | 20 |
population health | 20 |
cell signaling | 20 |
induced increase | 20 |
tumor tissue | 20 |
health insurance | 20 |
strong association | 20 |
molecular dynamics | 20 |
following surgery | 20 |
one way | 20 |
pulse oximetry | 20 |
gene polymorphisms | 20 |
systematic review | 20 |
ca concentration | 20 |
many cases | 20 |
level ii | 20 |
oxidized ldl | 20 |
coagulation parameters | 20 |
pediatric renal | 20 |
oxygen extraction | 20 |
china objective | 20 |
outcome measure | 20 |
paraffin sections | 20 |
found significant | 20 |
one patients | 20 |
stress conditions | 20 |
middle east | 20 |
cardiopulmonary resuscitation | 20 |
gastric cancer | 20 |
tnf levels | 20 |
differences among | 20 |
catalytic activity | 20 |
widely distributed | 20 |
two months | 20 |
los angeles | 20 |
potential target | 20 |
adult ed | 20 |
human heart | 20 |
analyses revealed | 20 |
will help | 20 |
meld score | 20 |
mg daily | 20 |
unclear whether | 20 |
continuously monitored | 20 |
laboratory rabbits | 20 |
daily dose | 20 |
independent variables | 20 |
cell injury | 20 |
lung diseases | 20 |
free survival | 20 |
human il | 20 |
two children | 20 |
mean number | 20 |
severe allergic | 20 |